MNKD MannKind Corporation

1.09
+0.05  (+5%)
Previous Close 1.04
Open 1.04
Price To Book -1.06
Market Cap 206,681,577
Shares 189,616,126
Volume 2,378,604
Short Ratio
Av. Daily Volume 2,128,477

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. Edited Transcript of MNKD earnings conference call or presentation 7-Aug-19 9:00pm GMT
  2. MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript
  3. MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights
  4. MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform
  5. MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019
  6. Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3
  7. MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants
  8. MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients
  9. MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
  10. What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)?
  11. MNKD: ADA Presentations: Positive Pediatric Data Lends Support for Anticipated Pivotal Study. Adult Data Highlights Benefits, Safety of Higher Doses
  12. MannKind to Present at the JMP Securities Life Sciences Conference
  13. MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions
  14. Afrezza® (insulin human) Inhalation Powder Approved in Brazil
  15. 2 Healthcare Stocks That Could Double Your Money
  16. The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
  17. MannKind Announces Afrezza® Distribution Agreement in Australia
  18. Why MannKind Is Up Big Today
  19. MNKD: Product Sales Up 49% on 71% Growth in Demand. Product Margin Continues to Expand